CD274 and cancer: On one side, if treatment with anti-PD-1/PDL-1 agents was responsible for better survival in several different cancers, on the other, after such treatments, ICIs can cause the onset of inflammatory side effects affecting any organ system, conditions defined as immune-related adverse events (IrAEs) (37).